Clinical Trial Update: Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

View source ↗

Summary

This clinical trial update reports ocular safety findings for patients receiving Macugen (pegaptanib) for neovascular age-related macular degeneration; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Pfizer | Conditions: Macular Degeneration | Status: COMPLETED | Results posted: 2012-12-11